Shopping Cart 0
Cart Subtotal
USD 0

Dare Bioscience Inc (DARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Dare Bioscience Inc (Dare Bioscience), formerly Cerulean Pharma Inc, is a clinical stage biopharmaceutical company that develops products for women's reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Its products include ovaprene, a clinical stage, non-hormonal contraceptive ring that provides protection over multiple weeks of use; and topical 5% sildenafil citrate cream for women with female sexual arousal disorders. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. Dare Bioscience is headquartered in San Diego, California, the US.

Dare Bioscience Inc (DARE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dare Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Dare Bioscience to Acquire CatSper Contraceptive Target from Hydra Biosciences 13

Venture Financing 14

Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 14

Cerulean Pharma Raises USD 13 Million In Venture Financing 15

Partnerships 16

Dare Bioscience Enters into Development and Option Agreement with Orbis Biosciences 16

Cerulean Pharma Enters into Partnership with Novartis 17

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 18

Cerulean Pharma Enters into Research Agreement with GOG Foundation 19

Merger 20

Dare Bioscience to Merge with Pear Tree Pharma 20

Licensing Agreements 21

Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 21

Dare Bioscience to Enter into Licensing Agreement with Strategic Science & Technologies 23

Equity Offering 25

Dare Bioscience to Raise USD4.1 Million in Public Offering of Shares 25

Dare Bioscience to Raise Funds through Public Offering of Shares 26

Dare Bioscience Plans to Raise up to USD10 Million in Public Offering of Shares 27

Dare Bioscience Raises USD20.7 Million in Equity Financing 28

Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 29

Cerulean Pharma Raises USD40 Million in Public Offering of Shares 31

Cerulean Pharma Raises USD1 Million in Private Placement of Shares 33

Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For USD 67 Million 34

Asset Transactions 36

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 36

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 37

Acquisition 38

Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 38

Dare Bioscience Inc-Key Competitors 39

Dare Bioscience Inc-Key Employees 40

Dare Bioscience Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Corporate Communications 42

Sep 17, 2018: Dare Bioscience names Greg Matz as board director 42

Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer 43

May 08, 2018: Dare Bioscience Expands Leadership Team, Appointing John Fair to Chief Business Officer 44

Apr 11, 2018: Jessica Grossman Joins Dare Bioscience Board of Directors 45

Jul 20, 2017: Dare Bioscience trading on The NASDAQ Capital Market under the symbol "DARE" 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dare Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dare Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Dare Bioscience to Acquire CatSper Contraceptive Target from Hydra Biosciences 13

Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 14

Cerulean Pharma Raises USD 13 Million In Venture Financing 15

Dare Bioscience Enters into Development and Option Agreement with Orbis Biosciences 16

Cerulean Pharma Enters into Partnership with Novartis 17

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 18

Cerulean Pharma Enters into Research Agreement with GOG Foundation 19

Dare Bioscience to Merge with Pear Tree Pharma 20

Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 21

Dare Bioscience to Enter into Licensing Agreement with Strategic Science & Technologies 23

Dare Bioscience to Raise USD4.1 Million in Public Offering of Shares 25

Dare Bioscience to Raise Funds through Public Offering of Shares 26

Dare Bioscience Plans to Raise up to USD10 Million in Public Offering of Shares 27

Dare Bioscience Raises USD20.7 Million in Equity Financing 28

Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 29

Cerulean Pharma Raises USD40 Million in Public Offering of Shares 31

Cerulean Pharma Raises USD1 Million in Private Placement of Shares 33

Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For USD 67 Million 34

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 36

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 37

Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 38

Dare Bioscience Inc, Key Competitors 39

Dare Bioscience Inc, Key Employees 40

Dare Bioscience Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Dare Bioscience Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Dare Bioscience Inc (Dare Bioscience), formerly Cerulean Pharma Inc, is a clinical stage biopharmaceutical company that develops products for women's reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Its products include ovaprene, a clinical stage, non-hormonal contraceptive ring that provides protection over multiple weeks of use; and topical 5% sildenafil citrate cream for women with female sexual arousal disorders. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. Dare Bioscience is headquartered in San Diego, California, the US.

Dare Bioscience Inc (DARE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dare Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Dare Bioscience to Acquire CatSper Contraceptive Target from Hydra Biosciences 13

Venture Financing 14

Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 14

Cerulean Pharma Raises USD 13 Million In Venture Financing 15

Partnerships 16

Dare Bioscience Enters into Development and Option Agreement with Orbis Biosciences 16

Cerulean Pharma Enters into Partnership with Novartis 17

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 18

Cerulean Pharma Enters into Research Agreement with GOG Foundation 19

Merger 20

Dare Bioscience to Merge with Pear Tree Pharma 20

Licensing Agreements 21

Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 21

Dare Bioscience to Enter into Licensing Agreement with Strategic Science & Technologies 23

Equity Offering 25

Dare Bioscience to Raise USD4.1 Million in Public Offering of Shares 25

Dare Bioscience to Raise Funds through Public Offering of Shares 26

Dare Bioscience Plans to Raise up to USD10 Million in Public Offering of Shares 27

Dare Bioscience Raises USD20.7 Million in Equity Financing 28

Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 29

Cerulean Pharma Raises USD40 Million in Public Offering of Shares 31

Cerulean Pharma Raises USD1 Million in Private Placement of Shares 33

Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For USD 67 Million 34

Asset Transactions 36

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 36

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 37

Acquisition 38

Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 38

Dare Bioscience Inc-Key Competitors 39

Dare Bioscience Inc-Key Employees 40

Dare Bioscience Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Corporate Communications 42

Sep 17, 2018: Dare Bioscience names Greg Matz as board director 42

Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer 43

May 08, 2018: Dare Bioscience Expands Leadership Team, Appointing John Fair to Chief Business Officer 44

Apr 11, 2018: Jessica Grossman Joins Dare Bioscience Board of Directors 45

Jul 20, 2017: Dare Bioscience trading on The NASDAQ Capital Market under the symbol "DARE" 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dare Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dare Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Dare Bioscience to Acquire CatSper Contraceptive Target from Hydra Biosciences 13

Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 14

Cerulean Pharma Raises USD 13 Million In Venture Financing 15

Dare Bioscience Enters into Development and Option Agreement with Orbis Biosciences 16

Cerulean Pharma Enters into Partnership with Novartis 17

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 18

Cerulean Pharma Enters into Research Agreement with GOG Foundation 19

Dare Bioscience to Merge with Pear Tree Pharma 20

Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 21

Dare Bioscience to Enter into Licensing Agreement with Strategic Science & Technologies 23

Dare Bioscience to Raise USD4.1 Million in Public Offering of Shares 25

Dare Bioscience to Raise Funds through Public Offering of Shares 26

Dare Bioscience Plans to Raise up to USD10 Million in Public Offering of Shares 27

Dare Bioscience Raises USD20.7 Million in Equity Financing 28

Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 29

Cerulean Pharma Raises USD40 Million in Public Offering of Shares 31

Cerulean Pharma Raises USD1 Million in Private Placement of Shares 33

Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For USD 67 Million 34

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 36

Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 37

Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 38

Dare Bioscience Inc, Key Competitors 39

Dare Bioscience Inc, Key Employees 40

Dare Bioscience Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Dare Bioscience Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.